The dynamics of drug-target interactions: Drug-target residence time and its impact on efficacy and safety

Expert Opinion on Drug Discovery

Volumn 5, Issue 4, 2010, Pages 305-310

  Copeland, Robert A ^a  

^a EPIZYME INC   (United States)

Author keywords

Drug target interactions; Efficacy; Koff; Residence time; Safety

Indexed keywords

CANDESARTAN; CHLORPROMAZINE; CLOPIDOGREL; DARUNAVIR; DESLORATADINE; FINASTERIDE; HIRUDIN; LAPATINIB; PENTOSTATIN; RETAPAMULIN; ROXIFIBAN; SAXAGLIPTIN;

BLEEDING; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOLECULAR DYNAMICS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 77950197835     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441003677725     Document Type: Review

References (30)

1. Ehrlich P. Chemotherapeutics: scientific principles, methods and results. Lancet 1913;182:445-451
2. Fischer E. Einfluss der configuration auf die wirkung der enzyme. Ber Dtsch Chem Ges 1894;27:2985-2993
3. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol 1988;61:201-301
4. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nature Rev Drug Discov 2004;3:27-41
5. Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nature Chem Biol 2009;5:789-796
6. Copeland RA. Enzymes: a practical introduction to structure, mechanism and data analysis. Wiley, New York; 2000
7. Copeland RA. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Wiley, Hoboken, NJ, USA; 2005
8. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nature Rev Drug Discov 2006;5:730-739
9. Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008;47:5481-5492
10. Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 2006;27:355-359
11. Szczuka A, Wennerberg M, Packeu A, Vauquelin G. Molecular mechanisms for the persistent bronchodilatory effect of the beta2-adrenoceptor agonist salmeterol. Brit J Pharmacol 2009;158:183-194
12. Vauquelin G, Fierens F, Van Liefde I. Long-lasting angiotesin Type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens 2006;24:S23-30
13. Zhang R, Monsma F. The importance of drug-target residence time. Current Opin Drug Discov Dev 2009;12:488-496
14. Weikl TR, von Deuster C. Selected-fit versus induced-fit protein binding: kinetic differences and mutational analysis. Proteins 2009;75:104-110
15. Ploeger BA, van der Graaf PH, Danhof M. Incorporating receptor theory in mechanism-based pharmacokineticpharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet 2009;24:3-15
16. Malany S, Hernandez LM, Smith WF, et al. Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Receptors Signal Transduct 2009;29:84-93
17. Tillotson B, Coco J, Whitebread N, et al. A novel pharmacodynamic assay to measure HSP90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors. American Association for Cancer Research Annual Meeting 2009; Abstract 1710
18. Lindström E, von Mentzer B, Påhlman I, et al. Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. J Pharmacol Exp Ther 2007;322:1286-1293
19. Lu H, England K, am Ende C, et al. Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem Biol 2009;4:221-231
20. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus Type 1 protease explain the potent antiviral activity and high genetic barrier. J Virology 2007;81:13845-13851
21. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909
22. Rajagopalan R, Misialek S, Stevens SK, et al. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveal tight binding and slow dissociation behavior. Biochemistry 2009;48:2559-2568
23. Lewandowicz A, Tyler P, Evans GB, et al. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem 2003;278:31465-31468
24. Bryant J, Post JM, Alexander S, et al. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets. Thrombosis Res 2008;122:523-532
25. Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov 2009;8:15-16
26. Cooper MA. Optical biosensors in drug discovery. Nature Rev Drug Discov 2002;1:515-528
27. Danielson UH. Integrating surface plasmon resonance biosensor-based interaction kinetic analysis into the lead discovery and optimization process. Future Med Chem 2009;1:1399-1414
28. Yan K, Madden L, Choudhry AE, et al. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother 2006;50:3875-3881
29. Kohout TA, Reijmers S, Finn KJ, et al. Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism. Mol Pharmacol 2007;72:238-247
30. Gabrielsson J, Dolgos H, Gillberg P-G, et al. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today 2009;14:358-372